inolimomab

an antibody to IL-2 receptor; used for induction of immunosuppression after liver transplantation

Also Known As:

BT 563; BT-563; BT563; Leukotac

Networked: 18 relevant articles (4 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        inolimomab: 18
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        inolimomab: 18
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        inolimomab: 18

Experts

1.	Michallet, Mauricette: 3 articles (01/2017 - 09/2005)
2.	Bay, Jacques-Olivier: 2 articles (01/2017 - 09/2005)
3.	Vernant, Jean-Paul: 2 articles (01/2017 - 09/2005)
4.	Yakoub-Agha, Ibrahim: 2 articles (01/2017 - 09/2005)
5.	Briones, Javier: 2 articles (03/2013 - 11/2006)
6.	Brunet, Salut: 2 articles (03/2013 - 11/2006)
7.	Martino, Rodrigo: 2 articles (03/2013 - 11/2006)
8.	Piñana, Jose Luis: 2 articles (03/2013 - 11/2006)
9.	Sierra, Jorge: 2 articles (03/2013 - 11/2006)
10.	Valcárcel, David: 2 articles (03/2013 - 11/2006)

Related Diseases

1.	Graft vs Host Disease (Graft-Versus-Host Disease) 11/01/2006 - "Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease." 01/01/2007 - "Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease." 03/01/2013 - "Updated experience with inolimomab as treatment for corticosteroid-refractory acute graft-versus-host disease." 10/01/2002 - "OPi (formerly Orphan Pharma International) is developing inolimomab, an anti-interleukin-2 receptor (CD25) monoclonal antibody for the potential treatment of acute graft versus host disease. " 12/01/1994 - "Treatment of steroid-resistant acute graft-vs-host disease after allogeneic marrow transplantation with anti-interleukin-2 receptor antibody (BT563)."
2.	Tachycardia (Tachyarrhythmias) 08/01/1998 - "The introduction of quadruple induction therapy after liver transplantation with the murine anti-interleukin-2 receptor (IL-2R) antibody (BT563) has decreased the incidence of serious side effects, such as tachycardia, hypertension, rash, fever and nausea since it does not lyse its target cell. "
3.	Nausea 08/01/1998 - "The introduction of quadruple induction therapy after liver transplantation with the murine anti-interleukin-2 receptor (IL-2R) antibody (BT563) has decreased the incidence of serious side effects, such as tachycardia, hypertension, rash, fever and nausea since it does not lyse its target cell. "
4.	Hypertension (High Blood Pressure) 08/01/1998 - "The introduction of quadruple induction therapy after liver transplantation with the murine anti-interleukin-2 receptor (IL-2R) antibody (BT563) has decreased the incidence of serious side effects, such as tachycardia, hypertension, rash, fever and nausea since it does not lyse its target cell. "
5.	Fever (Fevers) 08/01/1998 - "The introduction of quadruple induction therapy after liver transplantation with the murine anti-interleukin-2 receptor (IL-2R) antibody (BT563) has decreased the incidence of serious side effects, such as tachycardia, hypertension, rash, fever and nausea since it does not lyse its target cell. "

Related Drugs and Biologics

1.	inolimomab
2.	Steroids
3.	Monoclonal Antibodies
4.	Cyclosporine (Ciclosporin)
5.	Adrenal Cortex Hormones (Corticosteroids)
6.	Interleukins
7.	Interleukin-2 Receptors (IL 2 Receptor)
8.	Antibodies
9.	Etanercept (Enbrel)
10.	Biosimilar Pharmaceuticals

Related Therapies and Procedures

1.	Therapeutics
2.	Liver Transplantation
3.	Hematopoietic Stem Cell Transplantation
4.	Photopheresis
5.	Transplantation